An emerging AI-focused company is experiencing a severe market chill. On April 22, the stock price of QINGSONG HEALTH fell another 16.6%, reducing its market capitalization to HK$10.37 billion. In just three days, HK$23 billion in market value has evaporated.
The steep decline began on the afternoon of April 20, when the stock price plummeted from around HK$153 per share to HK$55.1, a drop of over 60% for the day. The following morning, Chairperson and CEO Yang Yin issued an announcement stating that the board confirmed business operations were normal and that no major shareholders or directors had sold any shares. As the single largest shareholder, with a personal stake exceeding 23%, Yang has seen her paper wealth shrink by over HK$5 billion.
Unfortunately, Yang's response failed to reassure the market, and the stock's decline continued. When contacted, QINGSONG HEALTH stated it was still assessing the specific situation. "The company has a small free float, with a daily turnover rate often below 1%. Trading volume is very low relative to its market cap," explained Kuang Yuqing, founder of Lens Consulting, noting that such Hong Kong stocks are prone to sharp fluctuations, especially when share ownership is concentrated.
A key trigger for the sell-off occurred on April 17, when CFO Wang Jing and independent non-executive director Bai Kun both announced their resignations, just over four months after the company's listing. Yang Yin had led the team to a listing on the Hong Kong Stock Exchange at the end of 2025. Catching the "AI + healthcare" trend, QINGSONG HEALTH attracted significant attention during its IPO, with an oversubscription rate of 1,421 times, making it a market darling. Its IPO price was HK$22.68, and after a strong debut, the stock climbed steadily, reaching a peak of HK$162.7 in late March, pushing its valuation past HK$33 billion.
Soon after, Wang Jing's resignation applied the brakes to the soaring stock. She stepped down as CFO, publicly stating she needed to "devote more time to other personal matters." Management adjustments following the release of a company's first annual report are not uncommon in Hong Kong-listed firms, especially for transitional executives or independent directors appointed around the IPO time. However, Wang's role was particularly significant. Aged 51 and a finance professional graduate of the Central University of Finance and Economics, with experience at PwC and EY where she rose to partner, Wang had joined the Qingsong Group in July 2015, just six months after Yang. She had long served as CFO and became an executive director in February 2017, overseeing finance, investment, capital market activities, corporate governance, and legal affairs. Essentially, she and Yang had been board-level partners for a decade, making her a co-founder in spirit. Her total compensation for 2025 exceeded 4 million yuan, and her shareholding once reached a peak market value of over 400 million yuan.
According to the announcement, Yang has appointed Wang as a senior advisor to continue providing strategic and capital operation support. Nevertheless, her departure so soon after the listing inevitably sparked market concerns about the company's fundamentals. "The impact of personnel changes on the stock price must be considered alongside recent market sentiment," Kuang Yuqing added, suggesting that high-level changes coinciding with sensitive periods, such as financial rumors, can easily fuel speculation.
The business built by Yang Yin is a health and insurance services platform. In 2025, its revenue reached 1.256 billion yuan, up 32.9%, but it reported a loss of 380 million yuan due to changes in the fair value of preferred shares. Excluding this, net profit was 92 million yuan, a 9% year-on-year increase. Revenue primarily comes from two segments. The main contributor is health services, providing medical科普, research support, and early screening services to enterprises and users, generating 926 million yuan in revenue last year, over 70% of the total. This segment showed strong growth, increasing over 50% annually, but it is not very profitable. The largest revenue stream within it, digital marketing (科普 services), has a gross margin of only 13.6%.
Yang's core profitable business is insurance-related. In 2025, insurance services revenue was 327 million yuan, accounting for less than 30% of total revenue but boasting high margins. For example, insurance brokerage, where the team assists partners in selling products via an online platform, has a gross margin nearing 50%. The most profitable segment is insurance technology services, which involves using big data analytics to help clients understand coverage needs and improve marketing and service efficiency, offering intelligent operations, risk control, and monitoring. The technical service fees Yang's team received in 2025 amounted to 221 million yuan, with a remarkably high gross margin of 97%.
The weakness of the insurance services segment lies in its diminishing growth, which slowed to just 1.6% annually. Previously, insurance-related business once contributed up to 70% of revenue with an overall gross margin above 80%. In June 2024, to meet listing requirements, Yang spun off the critical illness crowdfunding platform "Qingsongchou," losing a major traffic source. This led to lower insurance conversion rates and reduced the overall gross margin to 34.6%. Fundamentally, Yang's dilemma is that the high-growth parts of QINGSONG HEALTH are not very profitable, while the profitable parts are losing growth momentum. Such fundamentals, supporting a high valuation of around HK$30 billion, make the stock vulnerable to deep corrections upon any negative news.
Coming from an investment background, Yang was fortunate to list during a wave of AI application enthusiasm. She has crafted an "AI + health" narrative for QINGSONG HEALTH, pledging to advance a dual-engine strategy focused on "health + artificial intelligence," emphasizing five key areas like deepening AI technology empowerment and expanding the integrated health service ecosystem. The team's self-developed AIcare technology stack is embedded in five core scenarios: content creation, intelligent underwriting, risk prediction, claims review, and health management. Following the rise of AI agents, the team launched the "Zhengyuanfang · MedClaw Collaborator" in March, covering evidence-based diagnosis and treatment support, multi-guideline consistency checks, case discussions, and research assistance.
AI technology is still in the investment phase and has not yet yielded commercial returns, which temporarily inflated the valuation. On the flip side, the barriers to AI may not be exceptionally high, and monetization is challenging. In 2025, Yang's team spent only 75.589 million yuan on R&D, a level of investment that may not convince the market of its technical capabilities. Meanwhile, sales and marketing expenses reached 213 million yuan, growing 34.81%, outpacing revenue growth. Kuang Yuqing indicated this often signals increasing difficulty in marketing conversion, a declining return on investment, and pressure on sustained business growth.
Notably, during its IPO, QINGSONG HEALTH issued only 26.54 million shares globally at HK$22.68 per share, raising about HK$600 million, with just one cornerstone investor, "Aoqin Heming," subscribing to 4.8 million shares for 100 million yuan. Such a small free float makes the stock susceptible to manipulation by large funds, leading to high volatility.
A greater challenge for Yang may arrive in just over two months. iFind data shows that in early July, QINGSONG HEALTH will face its first lock-up expiration, involving 14 shareholders and 126 million shares, representing over 60% of the total share capital. At the current price, this amounts to approximately HK$6.3 billion. "The lock-up expiration will impact the stock price," Kuang Yuqing remarked. If recent volatility fails to quickly restore confidence, investors might develop a fear-based outlook and seek to lock in profits. Based on the IPO price, as of April 22, investors still hold a paper gain of 1.2 times. However, it remains uncertain whether these paper profits will still be intact by July.
Comments